LON:GSK GSK (GSK) Share Price, News & Analysis GBX 1,476 +7.00 (+0.48%) As of 12:26 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesSustainabilityBuy This Stock About GSK Stock (LON:GSK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GSK alerts:Sign Up Key Stats Today's Range 1,462.50▼ 1,47850-Day Range 1,344▼ 1,492.5052-Week Range 1,242.50▼ 1,678.68Volume1.86 billion shsAverage Volume23.27 million shsMarket Capitalization£59.56 billionP/E Ratio1,784.76Dividend Yield0.04%Price TargetGBX 1,637.50Consensus RatingHold Company Overview GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Read More GSK Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreGSK MarketRank™: GSK scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageGSK has only been the subject of 4 research reports in the past 90 days.Read more about GSK's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 1,784.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 276.92.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 1,784.76, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 75.73.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GSK. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 4.36%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 74.97%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about GSK's dividend. Sustainability and ESG4.4 / 5Environmental Score-1.56 Short InterestThere is no current short interest data available for GSK. News and Social Media2.1 / 5News Sentiment0.71 News SentimentGSK has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GSK this week, compared to 6 articles on an average week.Search Interest37 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, GSK insiders have bought more of their company's stock than they have sold. Specifically, they have bought £27,446.69 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 0.20% of the stock of GSK is held by insiders.Percentage Held by Institutions56.95% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GSK's insider trading history. Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GSK Stock News HeadlinesInsider Buying: GSK plc (LON:GSK) Insider Buys 9 Shares of StockAugust 13, 2025 | insidertrades.comWave Life Sciences drops after trial data for GSK-partnered RNA-editing therapySeptember 3 at 10:53 AM | msn.comRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.September 5 at 2:00 AM | Investors Alley (Ad)Maze Therapeutics Appoints Misbah Tahir as Chief Financial OfficerSeptember 2 at 7:30 AM | quiverquant.comQDoes GSK Offer Value After a 4.5% Rise and Pharma Tariff Uncertainty in 2025?August 29, 2025 | finance.yahoo.comMHRA approves GSK’s oral antibiotic for UTIs in femalesAugust 29, 2025 | finance.yahoo.comGSK (LON:GSK) Receives "Buy" Rating from Shore CapitalAugust 29, 2025 | americanbankingnews.comGSK Vault CRM rollout a ‘key milestone’ for Veeva, says Raymond JamesAugust 25, 2025 | msn.comSee More Headlines GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at GBX 1,346.50 at the beginning of the year. Since then, GSK stock has increased by 9.6% and is now trading at GBX 1,476. How were GSK's earnings last quarter? GSK plc (LON:GSK) announced its earnings results on Wednesday, July, 30th. The company reported $75.30 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a trailing twelve-month return on equity of 18.08%. How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include AstraZeneca (AZN), Vodafone Group Public (VOD), Lloyds Banking Group (LLOY), Secure Trust Bank (STB), Barclays (BARC), Meta Platforms (META) and Intel (INTC). Company Calendar Last Earnings7/30/2025Today9/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:GSK CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Price Target for GSKGBX 1,637.50 High Price TargetGBX 2,100 Low Price TargetGBX 1,400 Potential Upside/Downside+11.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)GBX 0.83 Trailing P/E Ratio1,782.95 Forward P/E Ratio8.38 P/E Growth1.24Net Income£2.50 billion Net Margins8.02% Pretax MarginN/A Return on Equity18.08% Return on Assets9.56% Debt Debt-to-Equity Ratio114.64 Current Ratio0.81 Quick Ratio0.73 Sales & Book Value Annual Sales£31.63 billion Price / Sales1.88 Cash FlowGBX 181.02 per share Price / Cash Flow8.15 Book ValueGBX 329.73 per share Price / Book4.47Miscellaneous Outstanding Shares4,035,541,000Free FloatN/AMarket Cap£59.50 billion OptionableNot Optionable Beta0.31 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (LON:GSK) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.